Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

High-dose opioid reversal spray no better than lower dose in field, US study finds

Published 02/08/2024, 01:47 PM
Updated 02/08/2024, 03:17 PM
© Reuters. The drug Naloxone sits on a table during a free Opioid Overdose Prevention Training class provided by Lourdes Hospital in Binghamton, New York, U.S., April 5, 2018. REUTERS/Andrew Kelly/File photo

(Reuters) - A high-dose version of the opioid reversal spray naloxone, made by Hikma Pharmaceuticals (OTC:HKMPY), did not result in an increased survival rate compared with lower-dose versions of the drug when administered in emergency situations by New York law enforcement, according to a U.S. study.

The analysis also suggests that those given the higher 8 milligram strength spray were more than twice as likely to experience opioid withdrawal symptoms compared to other sprays such as Narcan that use a 4 mg dose.

Naloxone rapidly reverses or blocks the effects of opioids, restoring normal respiration, especially when given within minutes of the first signs of an overdose.

The Hikma version, sold under the brand name Kloxxado, was approved in 2021 after U.S. Food and Drug Administration advisers and National Institutes of Health reports suggested that a high-dose version was needed to respond to overdoses by more potent opioids such as fentanyl.

The U.S. opioid epidemic has caused more than a half million overdose deaths over more than two decades, with fentanyl and synthetic versions a major culprit in recent years, according to government data.

According to the field study, 99.0% of those who received 8 mg of intranasal naloxone survived, as did 99.2% of those who received 4 mg.

The study, conducted by New York employees and published on Thursday by the U.S. Centers for Disease Control and Prevention, analyzed 436 detailed reports from New York State Police troopers from March 26, 2022 through Aug. 16, 2023. The reports included body-worn camera footage.

This was the first real-world data comparing the two doses and aligns with an earlier systemic review of reports from emergency departments, the study authors said.

Among those who received 8 mg naloxone, 37.6% showed signs of opioid withdrawal including vomiting, compared with 19.4% for those who got the 4 mg dose, the data showed.

Opioid withdrawal symptoms associated with the use of naloxone include vomiting, disorientation, lethargy, shivering, diarrhea and increased heart rate.

"Those on the frontlines of this public health epidemic need all FDA-approved treatment options available to them, which is why Hikma provides 8 mg nasal Kloxxado and generic injectable naloxone options to help meet the urgent needs of patients and communities," the company said in a statement.

The study authors said their findings were limited by the fact that police personnel were not medical providers and that there may have been inconsistencies in the classification of post-naloxone administration symptoms.

© Reuters. FILE PHOTO: Paramedics display a dose of the opioid overdose reversal drug Narcan, or Naloxone Hydrochloride, in an ambulance in Peabody, Massachusetts, U.S., August 8, 2017. REUTERS/Brian Snyder/File Photo

Emergent Biosolutions (NYSE:EBS)' Narcan, the first nasal spray emergency treatment for opioid overdose, was approved by the FDA in 2015 as a prescription drug at a 4 mg dose.

Apart from Emergent, Israel-based Teva Pharmaceutical Industries (NYSE:TEVA), Padagis Israel Pharmaceuticals and Amphastar Pharmaceuticals (NASDAQ:AMPH) also manufacture 4 mg versions of naloxone nasal spray.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.